Marlborough, MA-based Sepracor was quick to reassure the Boston biotech community that Dainippon's $2.6 billion acquisition of the company wouldn't interfere with its local operations. The Japanese company is widely viewed as most interested in Sepracor's sales platform as a launch point for new products. Analysts, meanwhile, have been offering some varying opinions as to whether another bidder for the company might suddenly appear. Report [1]
Links:
[1] http://www.boston.com/business/healthcare/articles/2009/09/04/sepracor_vows_to_stay_in_mass/